Edesa Biotech, Inc. has announced the pricing of an underwritten public offering, which includes 3,870,500 common shares and accompanying common share warrants, along with pre-funded warrants for additional shares. The total expected gross proceeds from the offering are about $25 million. The offering is set to close on or around August 21, 2026, pending customary conditions, and Edesa intends to use the funds for general corporate purposes, including research and development. Guggenheim Securities is the sole book-running manager for this offering.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/08/20/tmt-newswire/globenewswire/edesa-biotech-announces-pricing-of-250-million-public-offering/2408905
